The issue of cannabis drug interactions is becoming increasingly important as the market evolves. Today, the discussion extends beyond traditional CBD and THC to include emerging molecules like delta-8-THC, HHC, and other next-generation cannabinoids. For adult consumers in France and Europe, this means one crucial point: a product may appear legal, well-presented, and modern, yet still raise serious questions about its compatibility with certain medications.
Recent studies generally point in the same direction: cannabinoids can alter how the body metabolizes certain medications, particularly via liver enzymes of the CYP450 family. However, the risk is neither uniform nor automatic. It depends on the specific molecule consumed, the dose, the frequency of use, the form of the product, and, of course, any other medications being taken concurrently. Here's what the latest data says, presented in a clear and helpful way to better understand the issues.
Why cannabis drug interactions attracting so much attention?
Scientific reviews published in 2024 confirm that CBD and THC can inhibit several CYP450 enzymes, with particularly strong signals observed for CYP3A4, CYP2C19, and CYP2C9. These enzymes play a crucial role in the elimination of many medications. When their activity is inhibited, the concentration of certain drugs can increase, potentially leading to adverse effects or a relative overdose.
What stands out strongly from recent publications is that the best-documented interactions primarily involve drugs with a narrow therapeutic index. In other words, treatments for which a small change in concentration can have significant clinical consequences. The most frequently cited examples are warfarin, tacrolimus, clobazam, and certain antiepileptics.
The authors emphasize, however, an important point: despite the increasing number of warnings, human data remains limited. Many alerts are based on mechanistic studies, isolated clinical observations, or small trials. The message, therefore, is not one of "general panic," but rather "intelligent caution," especially for people taking multiple medications, the elderly, or those undergoing sensitive treatment.
CBD, THC and liver enzymes: the heart of the mechanism
The main mechanism currently accepted is pharmacokinetic. In other words, cannabinoids can modify the absorption, metabolism, or elimination of a drug, rather than acting directly synergistically or antagonistically at the receptor level. Recent reviews also highlight that the evidence is stronger for enzyme-related interactions than for pharmacodynamic interactions in patients.
A human study published in 2023 in healthy adults supported the idea that CBD is both a reversible and a time-dependent inhibitor of several CYP enzymes. THC also shows effects on metabolism, although the exact profile can vary depending on the enzyme studied and the doses administered. This helps explain why two cannabis products can have very different effects.
More recently, a 2025 mechanistic study on human hepatocytes added a crucial nuance: CBD and THC don't just inhibit enzymes; they can also induce certain enzymes depending on the context and duration of exposure. This point is vital because it suggests that an effect observed after a single dose doesn't necessarily reflect what happens with chronic use. In other words, timing is just as important as the molecule itself.
The medications most affected according to recent studies
Of all the drug-cannabinoid combinations studied, warfarin remains one of the most frequently reported cases. The reason is well known: this drug is highly sensitive to variations in metabolism, particularly via CYP2C9, and increased exposure can lead to changes in the INR. Recent reviews therefore continue to classify this association among the most concerning.
Tacrolimus is another strong indicator. This immunosuppressant, metabolized notably by CYP3A4, also has a narrow therapeutic index. Reviews from 2024 and more recent analyses regularly cite it among interactions requiring high vigilance. In transplant patients or those under close monitoring, self-medication with cannabinoids should never be taken lightly.
Clobazam is one of the most striking examples in neurology. Recent studies frequently find it involved in interactions with CBD, consistent with the latter's effect on certain enzymatic pathways involved in benzodiazepine metabolism. More broadly, publications remind us that psychotropic and neurological medications are often implicated in reports related to CBD, which reinforces the importance of individualized medical monitoring.
The product consumed significantly changes the level of risk
A key point in recent reviews is that one should not rely solely on the label "cannabis." The risk of interaction depends heavily on the exact type of product: isolated CBD, broad-spectrum extract, THC-rich formulation, full-spectrum product, or synthetic or semi-synthetic cannabinoid. Two visually similar oils can therefore have very different implications depending on their actual composition.
This distinction is particularly important in the world of wellness hemp and next-generation cannabinoids. A product that is rigorously formulated, lab-tested, and properly labeled already provides a better basis for evaluation than one whose actual content is unclear. For the user, this means that buying a tested and compliant product is not just a matter of quality, but also of clarity regarding potential risks.
Systematic reviews published in 2024 also remind us that many existing studies rely on small samples and highly heterogeneous products. This is one of the reasons why it is difficult to translate every biological signal into a universal clinical rule. Hence the importance of not too hastily extrapolating a result obtained with a concentrated oral form of CBD to all the flowers, resins, or oils available on the market.
Delta-8-THC, HHC and emerging molecules: increased caution
Delta-8-THC is no longer considered simply a “milder” version of THC in terms of interactions. A 2025 in vitro study showed that delta-8-THC and some of its metabolites inhibit several major liver enzymes, with a high risk of interactions, especially with oral use. This is an important warning for consumers attracted to these alternatives marketed as milder or more readily available.
Regarding semi-synthetic cannabinoids, such as HHC, concerns stem primarily from the gap between the pace of market development and the pace of research. A 2025 study highlighted that these substances are marketed as legal substitutes for cannabis or THC and that they act on CB1 receptors in vitro. However, their drug interaction profile remains poorly characterized, creating a significant area of uncertainty.
This discrepancy is now one of the major underlying issues. Consumers can be exposed to new molecules even before robust clinical data are available. In practice, the newer a molecule is, the more conservative a approach should be adopted if medical treatment is underway. The absence of evidence is not proof of the absence of risk.
Why clinical data is still imperfect
Narrative and systematic reviews from 2024 converge on this observation: human pharmacokinetic data are still too limited to answer all questions. Available studies vary considerably in dose, formulation, treatment duration, and measured endpoints. This heterogeneity complicates interpretation and explains why some warnings remain largely precautionary.
Another important limitation is that many studies focus on healthy adults, whereas real-world clinical practice often involves people taking multiple medications, sometimes with chronic conditions, advanced age, or impaired liver function. Therefore, results obtained in laboratory or controlled trials do not always translate directly to everyday use.
Signals have even been reported in pediatric patients, with a 2025 analysis combining published cases and FAERS data in those under 18. While this article concerns a different population than that targeted by adult CBD products, it underscores a crucial point: interactions are not merely a theoretical debate. They also emerge in real-world reports.
What this changes in concrete terms for users and professionals
Recent literature increasingly presents cannabinoid-drug interactions as a topic for medication reconciliation. In practical terms, this means that before trying or resuming use of a CBD, THC, or emerging cannabinoid product, it is helpful to review all of one's treatments: prescriptions, self-medication, supplements, herbs, and consumption habits.
This approach is particularly important for older adults, people taking anticoagulants, antiepileptics, immunosuppressants, or psychotropic drugs, as well as anyone taking multiple medications simultaneously. Recent reviews also encourage the use of practical tools, such as online cannabinoid interaction checkers, in addition to consulting a pharmacist or doctor.
For reputable brands and retailers, this situation underscores the need for clear information about product composition. A properly formulated oil, laboratory-tested and legally compliant, provides consumers with a more reliable basis for discussion with a healthcare professional. While not a guarantee of no interaction, it is a real step towards more responsible and better-regulated consumption.
In summary, recent studies show that drug interactions with cannabis are a serious reality, especially with CBD, THC, and drugs with a narrow therapeutic index such as warfarin, tacrolimus, or clobazam. The risk primarily stems from hepatic metabolism mechanisms, particularly via the CYP450 enzymes, but its magnitude varies depending on the dose, duration of use, and type of product consumed.
The most important point for users remains simple: the more concentrated, oral, innovative, or poorly documented a cannabinoid is, the more caution is required. In a rapidly evolving market, choosing analyzed, transparent, and compliant products is already a good starting point. However, if you are currently undergoing medical treatment, the best approach is always to check for potential interactions with a healthcare professional before using it regularly.
